Analysts Favor Biotech Growth Over SpaceX Valuation

Market analysts suggest that Space Exploration Technologies Corp. is unlikely to double its stock price over the next two to three years. This outlook stems from the company's current $2 trillion market capitalization, annual losses totaling nearly $5 billion, and the expectation of insider selling once the lockup period expires.

In contrast, financial experts identify three biotechnology companies with higher growth potential. ADMA Biologics has already achieved profitability, reporting a first-quarter net income of $407 million. The company's growth is supported by its flagship product, Asceniv, which received Food and Drug Administration approval in 2019.

Other high-potential firms include EyePoint Pharmaceuticals and Viking Therapeutics. EyePoint is awaiting mid-year data readouts for its drug Duravyu, targeting wet age-related macular degeneration and diabetic macular edema. Viking Therapeutics is conducting Phase 3 trials for its obesity candidate VK2735, with an oral version scheduled for late-stage study in the fourth quarter of 2026.